Vanda Pharmaceuticals Executive and Leadership Team

Mihael Polymeropoulos, the President, Chief Executive Officer & Chairman at Vanda Pharmaceuticals, directs the overarching corporate strategy and vision. Overseeing all major business units, Polymeropoulos ensures the company's biopharmaceutical research and development efforts align with its mission to create innovative medicines. This leadership role involves guiding the company's global expansion across North America, Europe, and Asia, leveraging genetics and genomics to advance drug discovery and commercialization. By championing novel therapeutic approaches, Mihael Polymeropoulos drives the development of pharmaceutical products designed to improve patient lives. The Chairman's oversight extends to clinical trial execution and the strategic direction of the company's commercial operations, solidifying Vanda Pharmaceuticals' market position.

Paul Jones, the Chief Financial Officer at Vanda Pharmaceuticals, manages all financial operations and fiscal strategy. Overseeing budgeting, forecasting, and financial reporting, Jones ensures robust financial health across the company's global operations in North America, Europe, and Asia. This critical role involves managing capital allocation to support research and development initiatives, particularly those leveraging genetics and genomics for drug discovery. Paul Jones directs the financial aspects of clinical trials and commercial strategies, ensuring efficient resource utilization. By maintaining strong financial discipline, the Chief Financial Officer supports Vanda Pharmaceuticals' commitment to developing innovative medicines and improving patient lives. Jones's financial stewardship is key to the company's sustained growth and market presence.

Kevin Moran, the Senior Vice President, Chief Financial Officer and Treasurer at Vanda Pharmaceuticals, oversees the company's comprehensive financial architecture and treasury functions. Managing financial planning, risk management, and investor relations, Moran ensures Vanda Pharmaceuticals maintains a strong financial foundation to support its global operations across North America, Europe, and Asia. This position involves directing capital deployment for cutting-edge research and development, particularly in areas utilizing genetics and genomics for drug discovery. Kevin Moran guides the financial oversight of clinical trials and commercial strategies, optimizing resource allocation for maximum impact. By ensuring fiscal integrity and strategic financial management, the Chief Financial Officer and Treasurer supports Vanda Pharmaceuticals' dedication to developing innovative medicines and enhancing patient well-being. Moran's financial leadership is crucial for the company's long-term sustainability and growth.

Joakim Wijkstrom, the Senior Vice President, Chief Marketing Officer at Vanda Pharmaceuticals, spearheads all marketing and commercialization strategies. Overseeing the go-to-market plans for innovative medicines, Wijkstrom ensures Vanda Pharmaceuticals effectively reaches patients and healthcare providers across North America, Europe, and Asia. This role involves translating complex scientific advancements, including those from genetics and genomics research, into compelling market narratives. Joakim Wijkstrom directs the development and execution of promotional campaigns and market access initiatives, driving product adoption and revenue growth. By fostering strong relationships with key stakeholders, the Chief Marketing Officer plays a vital part in advancing the company's mission to improve patient lives through novel therapeutic approaches. Wijkstrom's strategic marketing leadership is essential for Vanda Pharmaceuticals' global impact.